C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD
While complement-dependent cytotoxicity (CDC) is a known effector mechanism in aquaporin-4-immunoglobulin (Ig)G-positive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD), the role of CDC in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is less clear. We determined...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
24 August 2021
|
| In: |
Journal of neuroimmunology
Year: 2021, Volume: 360, Pages: 1-5 |
| ISSN: | 1872-8421 |
| DOI: | 10.1016/j.jneuroim.2021.577699 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jneuroim.2021.577699 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0165572821002265 
|
| Author Notes: | Florence Pache, Marius Ringelstein, Orhan Aktas, Ingo Kleiter, Sven Jarius, Nadja Siebert, Judith Bellmann-Strobl, Friedemann Paul, Klemens Ruprecht |
| Summary: | While complement-dependent cytotoxicity (CDC) is a known effector mechanism in aquaporin-4-immunoglobulin (Ig)G-positive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD), the role of CDC in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is less clear. We determined complement C3 and C4 plasma concentrations in patients with clinically stable AQP4-IgG+ NMOSD (n = 16), MOGAD (n = 15), early multiple sclerosis (MS, n = 19) and in healthy controls (HC, n = 18). C4 was lower in AQP4-IgG+ NMOSD than in MOGAD, MS and HC (p < 0.05, pairwise comparisons). C3 was lower in AQP4-IgG+ NMOSD than in MS (p = 0.034). These findings suggest subtle complement consumption in clinically stable AQP4-IgG+ NMOSD, but not in MOGAD. |
|---|---|
| Item Description: | Gesehen am 15.01.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1872-8421 |
| DOI: | 10.1016/j.jneuroim.2021.577699 |